These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36560576)

  • 1. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.
    Ziemssen T; Groth M; Ettle B; Bopp T
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.
    Ziemssen T; Schlegel E; Groth M; Ettle B; Bopp T
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.
    Ziemssen T; Groth M; Ettle B; Bopp T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2316422. PubMed ID: 38346223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC).
    Ziemssen T; Groth M; Rauser B; Bopp T
    Ther Adv Neurol Disord; 2022; 15():17562864221135305. PubMed ID: 36381503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC).
    Ziemssen T; Groth M; Winkelmann VE; Bopp T
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab.
    Bar-Or A; Aburashed R; Chinea AR; Hendin BA; Lucassen E; Meng X; Stankiewicz J; Tullman MJ; Cross AH
    Mult Scler Relat Disord; 2023 Nov; 79():104967. PubMed ID: 37769429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
    Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.
    Faissner S; Heitmann N; Plaza-Sirvent C; Trendelenburg P; Ceylan U; Motte J; Bessen C; Urlaub D; Watzl C; Overheu O; Reinacher-Schick A; Hellwig K; Pfaender S; Schmitz I; Gold R
    Front Immunol; 2022; 13():980526. PubMed ID: 36119053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
    Cross AH; Delgado S; Habek M; Davydovskaya M; Ward BJ; Cree BAC; Totolyan N; Pingili R; Mancione L; Hu X; Sullivan R; Su W; Zielman R; Gupta AD; Montalban X; Winthrop K
    Neurol Ther; 2022 Jun; 11(2):741-758. PubMed ID: 35284994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
    Flores-Gonzalez RE; Hernandez J; Tornes L; Rammohan K; Delgado S
    Mult Scler Relat Disord; 2021 Apr; 49():102777. PubMed ID: 33508573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
    Wallach AI; Schiebel M; Picone MA
    Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Korsen M; Huntemann N; Rolfes L; Müntefering T; Dobelmann V; Hermann AM; Kölsche T; von Wnuck Lipinski K; Schroeter CB; Nelke C; Regner-Nelke L; Ingwersen J; Pawlitzki M; Teegen B; Barnett MH; Hartung HP; Aktas O; Albrecht P; Levkau B; Melzer N; Ruck T; Meuth SG; Kremer D
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):978-985. PubMed ID: 35193952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
    Conte WL; Golzarri-Arroyo L
    Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
    Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
    Front Immunol; 2022; 13():942192. PubMed ID: 36275696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.